Three takeaways:
1. MiMedx develops regenerative and therapeutic biologics utilizing human placental tissue allografts. It is primarily involved in advanced wound care, spine and sports medicine.
2. Mr. Wright has over 30 years of experience in the pharmaceutical, biotech and medical devices industries and will begin his role on May 13, succeeding interim CEO David Coles.
3. Mr. Wright’s prior experience includes serving as president and CEO of Tampa, Fla.-based biotech company M2Gen Corp. and executive vice president, mergers and acquisitions, strategy and innovation at Israeli multinational pharmaceutical company, Teva Pharmaceutical Industries.
More articles on biologics:
California orthopedic surgeon treats 1st patients with CartiHeal’s Agili-C implant
BioBridge adds orthopedic surgeon to regenerative medicine advisory board
Misonix acquires Solys Medical for $97M — 5 Takeaways
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
